Charcoal - Kureha

Drug Profile

Charcoal - Kureha

Alternative Names: AST-120; Kremezin; Kremezin Fine Granules; MP-146; Zysa

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kureha Corporation
  • Developer Daiichi Sankyo Pharmaceutical (Shanghai); Kureha Corporation; Mitsubishi Tanabe Pharma Corporation; Ocera Therapeutics
  • Class Absorbents
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal failure
  • Discontinued Crohn's disease; Gastro-oesophageal reflux; Hepatic encephalopathy; Irritable bowel syndrome; Pouchitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Oct 2013 Discontinued - Phase-III for Renal failure in USA, Argentina, Brazil, Canada, the Czech Republic, France, Germany, Italy, Mexico, Poland, Puerto Rico, Russia, Spain and Ukraine (PO)
  • 08 Mar 2013 Discontinued - Clinical-Phase-Unknown for Renal failure in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top